BCR and B-cell chronic lymphocytic leukemia: Moreover, a recent study comparing twice a day and once a day dosing of acalabrutinib in patients with CLL showed that the lower BTK occupancy in the latter cases was associated with a lower degree of BCR pathway inhibition and a lower ORR [230].